Riik: Uus-Meremaa
keel: inglise
Allikas: Medsafe (Medicines Safety Authority)
Ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg;
Douglas Pharmaceuticals Limited
Ciprofloxacin hydrochloride 291.79 mg (equivalent to ciprofloxacin 250 mg)
250 mg
Film coated tablet
Active: Ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg Excipient: Colloidal silicon dioxide Magnesium stearate Maize starch Microcrystalline cellulose Opadry white OY-S-58910 Purified talc Purified water Sodium starch glycolate
Blister pack, PVC/PVDC/aluminium foil, 10, 30 tablets, 10
Prescription
Prescription
Dr Reddy's Laboratories Limited
Package - Contents - Shelf Life: Blister pack, PVC/PVDC/aluminium foil, 10, 30 tablets - 10 - 36 months from date of manufacture stored at or below 25°C
2002-04-30
DATA SHEET CIFRAN CIPROFLOXACIN HYDROCHLORIDE PH. EUR. 250 MG, 500 MG AND 750 MG FILM COATED TABLETS PRESENTATION Cifran 250 mg tablets: each tablet contains 291.79 mg ciprofloxacin hydrochloride, equivalent to 250 mg ciprofloxacin. Tablets are white to off-white, round, film-coated, embossed with ‘250’ on one side and plain on the other side. Cifran 500 mg tablets: each tablet contains 583.59 mg ciprofloxacin hydrochloride, equivalent to 500 mg ciprofloxacin. Tablets are white to off-white, caplet-shaped, film-coated, embossed with ‘500’ on one side and plain on the other side. Cifran 750 mg tablets: each tablet contains 875.39 mg ciprofloxacin hydrochloride, equivalent to 750 mg ciprofloxacin. Tablets are white to off-white, caplet-shaped, film-coated, embossed with ‘750’ on one side and plain on the other side. USES _ACTIONS _ Ciprofloxacin is a synthetic broad spectrum antibacterial agent (ATCCODE: J 01 MA 02). Ciprofloxacin is effective in vitro against virtually all gram-negative pathogens, including Pseudomonas aeruginosa. It is also effective against gram-positive pathogen such as staphylococci and streptococci. Anaerobes are generally less susceptible. Ciprofloxacin has a rapid bactericidal action, both in the proliferation phase and in the resting phase. During the proliferation phase of a bacterium a segmental twisting and untwisting of the chromosomes take place. An enzyme called DNA gyrase plays a decisive part in this process. Ciprofloxacin inhibits this DNA gyrase in a way that arrests the bacterial metabolism, since vital information can no longer be read from the bacterial chromosome. Resistance to ciprofloxacin develops slowly and in stages (multiple-step type). Plasmid-mediated resistance development of the kind that occurs with β-lactam antibiotics, aminoglycosides, and tetracyclines has not been observed with ciprofloxacin. It is of clinical interest t Lugege kogu dokumenti